Orifarm says it is “investing heavily” in the firm’s generics division to ensure future growth in the business, including an expansion of its laboratory in Skælskør, Denmark. The location in Skælskør houses Viminco, which Orifarm acquired in 2015 “as part of an increased strategic focus on retail medicine and niche products”, and employs approximately 100 staff.
Orifarm is planning to expand and synergise
Orifarm says it is “investing heavily” in the firm’s generics division to ensure future growth in the business, including an expansion of its laboratory in Skælskør, Denmark. The location in Skælskør houses Viminco, which Orifarm acquired in 2015 “as part of an increased strategic focus on retail medicine and niche products”, and employs approximately 100 staff.
More from Manufacturing
More from Business
• By
Lupin’s UK subsidiary acquired the British firm for an undisclosed sum of money, adding further assets into the company’s armamentarium.
• By
Following recent agreements signed by Hikma and Amneal, Viatris has become the latest company to reach a cash settlement resolving allegations that its practices fuelled the US’ deadly opioid epidemic.
• By
Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.